These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

68 related articles for article (PubMed ID: 12971333)

  • 1. New drug-device combination helps keep arteries open.
    FDA Consum; 2003; 37(4):6. PubMed ID: 12971333
    [No Abstract]   [Full Text] [Related]  

  • 2. Treatment of drug-eluting stent restenosis: a sandwich may not be the best combo.
    Belardi J
    Catheter Cardiovasc Interv; 2008 Apr; 71(5):599. PubMed ID: 18360848
    [No Abstract]   [Full Text] [Related]  

  • 3. Drug-eluting stent update 2007: part III: Technique and unapproved/unsettled indications (left main, bifurcations, chronic total occlusions, small vessels and long lesions, saphenous vein grafts, acute myocardial infarctions, and multivessel disease).
    Colombo A; Chieffo A
    Circulation; 2007 Sep; 116(12):1424-32. PubMed ID: 17875983
    [No Abstract]   [Full Text] [Related]  

  • 4. Long-term clinical outcomes after sirolimus-eluting stent implantation for treatment of restenosis within bare-metal versus drug-eluting stents.
    Whan Lee C; Kim SH; Suh J; Park DW; Lee SH; Kim YH; Hong MK; Kim JJ; Park SW; Park SJ
    Catheter Cardiovasc Interv; 2008 Apr; 71(5):594-8. PubMed ID: 18311841
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparative healing response after sirolimus- and paclitaxel-eluting stent implantation in a pig model of restenosis.
    Silva GV; Fernandes MR; Madonna R; Clubb F; Oliveira E; Jimenez-Quevedo P; Branco R; Lopez J; Angeli FS; Sanz-Ruiz R; Vaughn WK; Zheng Y; Baimbridge F; Canales J; Cardoso CO; Assad JA; Falotico R; Perin EC
    Catheter Cardiovasc Interv; 2009 May; 73(6):801-8. PubMed ID: 19309735
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Understanding the drug-eluting stent trials.
    Coolong A; Kuntz RE
    Am J Cardiol; 2007 Sep; 100(5A):17K-24K. PubMed ID: 17719349
    [TBL] [Abstract][Full Text] [Related]  

  • 7. New stents, hopes--and questions. After approval of a drug-coated cylinder, patients face wider options.
    Heart Advis; 2003 Jul; 6(7):1, 7. PubMed ID: 12921036
    [No Abstract]   [Full Text] [Related]  

  • 8. Cost analysis from two randomized trials of sirolimus-eluting stents versus paclitaxel-eluting stents in high-risk patients with coronary artery disease.
    Elezi S; Dibra A; Folkerts U; Mehilli J; Heigl S; Schömig A; Kastrati A
    J Am Coll Cardiol; 2006 Jul; 48(2):262-7. PubMed ID: 16843172
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Sirolimus-eluting vs paclitaxel-eluting stents -- the trials confirm differences in clinical outcome].
    Gil RJ
    Kardiol Pol; 2005 Nov; 63(5):574-6; discussion 577. PubMed ID: 16362868
    [No Abstract]   [Full Text] [Related]  

  • 10. Drug-eluting stent in saphenous vein graft lesions.
    Kornowski R
    Catheter Cardiovasc Interv; 2008 Jun; 71(7):894-5. PubMed ID: 18498140
    [No Abstract]   [Full Text] [Related]  

  • 11. Stent fracture-unusual cause of DES restenosis.
    Goyal BK
    Catheter Cardiovasc Interv; 2007 Jun; 69(7):993-4. PubMed ID: 17525958
    [No Abstract]   [Full Text] [Related]  

  • 12. Comparison of sirolimus-eluting stent, paclitaxel-eluting stent, and bare metal stent in the treatment of long coronary lesions.
    Kim YH; Park SW; Lee CW; Hong MK; Gwon HC; Jang Y; Lee MM; Koo BK; Oh DJ; Seung KB; Tahk SJ; Yoon J; Park SJ
    Catheter Cardiovasc Interv; 2006 Feb; 67(2):181-7. PubMed ID: 16400663
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sirolimus-eluting stents: safe and effective in the treatment of in-stent restenosis.
    Neumann FJ
    Catheter Cardiovasc Interv; 2005 Oct; 66(2):163-4. PubMed ID: 16158398
    [No Abstract]   [Full Text] [Related]  

  • 14. Drug-eluting stents for infrainguinal occlusive disease: progress and challenges.
    Tepe G
    Semin Vasc Surg; 2006 Jun; 19(2):102-8. PubMed ID: 16782516
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cost-effectiveness of the real-world use of drug-eluting stents at 9-month follow-up: results from the Sicilian DES Registry.
    Tamburino C; Barbagallo R; Capodanno D; di Matteo S; Colombo GL; Recchia M; Ciriminna S;
    J Cardiovasc Med (Hagerstown); 2009 Apr; 10(4):322-9. PubMed ID: 19430343
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparative characterization of cellular and molecular anti-restenotic profiles of paclitaxel and sirolimus. Implications for local drug delivery.
    Wessely R; Blaich B; Belaiba RS; Merl S; Görlach A; Kastrati A; Schömig A
    Thromb Haemost; 2007 Jun; 97(6):1003-12. PubMed ID: 17549304
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Drug-eluting stents: from randomized trials to the real world.
    Saia F; Degertekin M; Lemos PA; Serruys PW
    Minerva Cardioangiol; 2004 Oct; 52(5):349-63. PubMed ID: 15514571
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Drug-eluting stents.
    García-García HM; Vaina S; Tsuchida K; Serruys PW
    Arch Cardiol Mex; 2006; 76(3):297-319. PubMed ID: 17091802
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Drug-eluting coronary stents.
    Bonvini RF; Verin V
    N Engl J Med; 2005 Dec; 353(22):2404-8; author reply 2404-8. PubMed ID: 16320452
    [No Abstract]   [Full Text] [Related]  

  • 20. Restenosis: the mouse that roared.
    King SB
    Circulation; 2003 Jul; 108(3):248-9. PubMed ID: 12876132
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 4.